# OnCo record spectrum-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/spectrum-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "spectrum-pharmaceuticals" ;
  schema:name "Spectrum Pharmaceuticals"@en ;
  schema:alternateName "Spectrum Pharmaceuticals, Inc"@en, "Spectrum Pharmaceuticals, Inc."@en ;
  schema:description "Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023."@en ;
  schema:url <https://onco.cc/companies/spectrum-pharmaceuticals/>, <https://www.spectrumpharm.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7575301> ;
  schema:citation <https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals>, <https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/pralatrexate/> ;
  onco:companies <https://onco.cc/companies/acrotech-biopharma/> ;
  onco:terms <https://onco.cc/terms/neutropenia/> ;
  onco:trials <https://onco.cc/trials/nct04570423/> .